Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02344472
Title	Detect V / CHEVENDO (Chemo vs. Endo)
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Prof. Wolfgang Janni
Indications	Her2-receptor positive breast cancer
Therapies	Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab Capecitabine + Pertuzumab + Trastuzumab Exemestane + Pertuzumab + Ribociclib + Trastuzumab Letrozole + Pertuzumab + Ribociclib + Trastuzumab Eribulin + Pertuzumab + Trastuzumab Anastrozole + Pertuzumab + Ribociclib + Trastuzumab Goserelin + Pertuzumab + Ribociclib + Trastuzumab Pertuzumab + Trastuzumab + Vinorelbine Nab-paclitaxel + Pertuzumab + Trastuzumab Leuprolide + Pertuzumab + Ribociclib + Trastuzumab
Age Groups:	senior \| adult
Covered Countries	DEU

Facility	Status	City	State	Zip	Country	Details
University Hospital Ulm Gynecology/Obstetrics		Ulm			Germany	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field